$11.46
0.17%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US3968791083
Symbol
GLSI

Greenwich LifeSciences Inc Stock price

$11.46
-0.48 4.02% 1M
-0.24 2.05% 6M
+0.23 2.05% YTD
-2.56 18.26% 1Y
+2.83 32.79% 3Y
+5.71 99.30% 5Y
+5.71 99.30% 10Y
+5.71 99.30% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.02 0.17%
ISIN
US3968791083
Symbol
GLSI
Industry

Key metrics

Basic
Market capitalization
$156.2m
Enterprise Value
$153.1m
Net debt
positive
Cash
$3.1m
Shares outstanding
13.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
108.5
Financial Health
Equity Ratio
61.9%
Return on Equity
-623.1%
ROCE
-1,259.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.1m | -
EBIT
$-18.1m | $-13.1m
Net Income
$-18.0m | $-15.0m
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-72.3% | -
EBIT
-72.2% | 18.5%
Net Income
-76.0% | 4.8%
Free Cash Flow
-25.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-0.6
Short interest
16.0%
Employees
6
Rev per Employee
$0.0
Show more

Is Greenwich LifeSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Greenwich LifeSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Greenwich LifeSciences Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Greenwich LifeSciences Inc forecast:

Buy
86%
Hold
14%

Financial data from Greenwich LifeSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.58 3.58
132% 132%
-
- Research and Development Expense 15 15
62% 62%
-
-18 -18
72% 72%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -18 -18
72% 72%
-
Net Profit -18 -18
76% 76%
-

In millions USD.

Don't miss a Thing! We will send you all news about Greenwich LifeSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Greenwich LifeSciences Inc Stock News

Neutral
GlobeNewsWire
14 days ago
STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on ...
Neutral
GlobeNewsWire
15 days ago
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team.
Neutral
GlobeNewsWire
21 days ago
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania.
More Greenwich LifeSciences Inc News

Company Profile

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Head office United States
CEO Snehal Patel
Employees 6
Founded 2006
Website greenwichlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today